CPRX Share Price

Open 1.13 Change Price %
High 1.15 1 Day -0.01 -0.88
Low 1.12 1 Week 0.00 0.00
Close 1.12 1 Month -0.06 -5.08
Volume 183012 1 Year 0.00 0.00
52 Week High 1.58
52 Week Low 0.51
CPRX Important Levels
Resistance 2 1.15
Resistance 1 1.14
Pivot 1.13
Support 1 1.10
Support 2 1.09
NASDAQ USA Most Active Stocks
CTRP 47.59 1.13%
ADBE 119.47 -0.13%
FSLR 33.57 -8.33%
FSLR 33.57 -8.33%
CERN 55.37 0.18%
BIDU 186.01 0.21%
AAPL 137.11 0.30%
AAPL 137.11 0.30%
FB 136.12 1.79%
MASI 87.05 2.03%
More..
NASDAQ USA Top Gainers Stocks
VALV 0.05 66.67%
LOCM 0.09 50.00%
BASI 1.33 31.68%
WRES 0.09 28.57%
INAP 2.31 27.62%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
AETI 2.40 23.08%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
LIWA 0.01 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX)

CPRX Technical Analysis 1.5
As on 22nd Feb 2017 CPRX Share Price closed @ 1.12 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.99 & Sell for SHORT-TERM with Stoploss of 1.14 we also expect STOCK to react on Following IMPORTANT LEVELS.
CPRX Target for February
1st Target up-side 1.26
2nd Target up-side 1.35
3rd Target up-side 1.45
1st Target down-side 0.98
2nd Target down-side 0.89
3rd Target down-side 0.79
CPRX Other Details
Segment EQ
Market Capital 44575204.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.catalystpharma.com
CPRX Address
CPRX
355 Alhambra Circle
Suite 1500
Coral Gables, FL 33134
United States
Phone: 305-529-2522
Interactive Technical Analysis Chart Catalyst Pharmaceutical Partners, Inc. ( CPRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Catalyst Pharmaceutical Partners, Inc.
CPRX Business Profile
Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs targeting addiction diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy. As of December 31, 2011, the Company had two drugs in development: CPP-109 and CPP-115. of December 31, 2011, it was evaluating its drug candidate, CPP-109 for the treatment of cocaine addiction. As of December 31, 2011, the Company was in the early stages of developing CPP-115, another GABA aminotransferase inhibitor. It has identified two market opportunities that can be exploited by pharmacotherapies that inhibit GABA-aminotransferase (GABA-AT): drug addiction and epilepsy.